Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Big Dog's Boom Boom Room -- Ignore unavailable to you. Want to Upgrade?

To: TheBusDriver who wrote (79424)	2/4/2007 8:26:24 AM
From: Bearcatbob	Read Replies (1) \| Respond to of 206114

The 200 dma is a solid measure of support. If a holding breaks the 200 dma it is likely to be dead money for awhile - and likely to fall further. When that happens the challenge is to move on - or to have a da__ good reason to stay. Similary, a company braking the 200 dma on the way up is a good signal - escpecially if the 50 dma also crosses. dabum can likely expand on this with much more detail. I do not have the time for the depth of analysis that he does. marketbrowser.com Market Browser if a great free service to watch the dmas. Of interest, neither DBLE or DPTR show to have broken these averages despite recent drilling disappointments. Bob

To: TheBusDriver who wrote (79424)	2/4/2007 9:58:50 AM
From: rolatzi	Read Replies (2) \| Respond to of 206114

Re: Biotech I have been in Celgene (CELG) for the last 6 or 7 years and I think it has another two to three years to run. The company's drug Revlimid, after a most successful launch this past year, will receive approval in European Community in the next three months which will probably double the current market, and will see increased use for additional blood cancer indications over the next year or two. Another drug, CC-1004 is in mid-development phase (first indication for psoriasis) and will probably see positive research reports at the professional meetings in June (ASCO) and December (ASH) with approval likely sometime in late 2008 or 2009. A more speculative play is Dendreon (DNDN) which is being considered for approval with a prostate cancer vaccine (Provenge). The decision date is May of this year. The results of the human study may not be robust enough for approval, but the use is for terminal patients initially. There is probably a 75% chance for approval. However, the stock is heavily shorted, manipulated and is under priced. If not approved, it is likely to receive approvable letter which would require an additional human trial. Management is acting like they believe approval is assured but you never know. Ciao, rolatzi